Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Product containing precisely ciprofloxacin hydrochloride 100 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
|
Product containing precisely ciprofloxacin hydrochloride 250 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
|
Product containing precisely ciprofloxacin hydrochloride 500 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
|
Product containing precisely ciprofloxacin hydrochloride 750 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
|
Ciprofloxacin (as ciprofloxacin hydrochloride) 3 mg/g eye ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
|
Ciprofloxacin hydrochloride 0.3% solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
|
Ciprofloxacin hydrochloride 3.5mg solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
|
Ciprofloxacin hydrochloride + hydrocortisone 2.329mg/10mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
|
Ciprofloxacin 0.2% + hydrocortisone 1% otic solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
|
Ciprofloxacin+hydrocortisone |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
|
Ciprofloxacin hydrochloride + hydrocortisone 2.329mg/10mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
|
Ciprofloxacin (as ciprofloxacin hydrochloride) 3 mg/mL eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
|
Product containing precisely ciprofloxacin hydrochloride 100 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely ciprofloxacin hydrochloride 100 milligram/1 each conventional release oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely ciprofloxacin hydrochloride 250 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely ciprofloxacin hydrochloride 250 milligram/1 each conventional release oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely ciprofloxacin hydrochloride 500 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely ciprofloxacin hydrochloride 500 milligram/1 each conventional release oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely ciprofloxacin hydrochloride 750 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely ciprofloxacin hydrochloride 750 milligram/1 each conventional release oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely ciprofloxacin hydrochloride 100 milligram/1 each conventional release oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely ciprofloxacin hydrochloride 250 milligram/1 each conventional release oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely ciprofloxacin hydrochloride 500 milligram/1 each conventional release oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely ciprofloxacin hydrochloride 750 milligram/1 each conventional release oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Ciprofloxacin (as ciprofloxacin hydrochloride) 3 mg/mL eye drops |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Ciprofloxacin (as ciprofloxacin hydrochloride) 750 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely ciprofloxacin (as ciprofloxacin hydrochloride) 250 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Ciprofloxacin (as ciprofloxacin hydrochloride) 500 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely ciprofloxacin (as ciprofloxacin hydrochloride) 100 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Ciprofloxacin (as ciprofloxacin hydrochloride) 3 mg/g eye ointment |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely ciprofloxacin (as ciprofloxacin hydrochloride) 100 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Ciprofloxacin (as ciprofloxacin hydrochloride) 3 mg/mL and dexamethasone 1 mg/mL ear suspension |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
2 |
Product containing precisely ciprofloxacin (as ciprofloxacin hydrochloride) 2 milligram/1 milliliter and hydrocortisone 10 milligram/1 milliliter conventional release ear suspension (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely ciprofloxacin (as ciprofloxacin hydrochloride) 250 milligram and tinidazole 300 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely ciprofloxacin (as ciprofloxacin hydrochloride) 25 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely ciprofloxacin (as ciprofloxacin hydrochloride) 3 milligram/1 milliliter and fluocinolone acetonide 250 microgram/1 milliliter conventional release solution for ear drops (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely ciprofloxacin (as ciprofloxacin hydrochloride) 3 milligram/1 milliliter conventional release solution for ear drops (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |
Ciprofloxacin (as ciprofloxacin hydrochloride) 574.9 mg and ciprofloxacin 425.2 mg prolonged-release oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Ciprofloxacin hydrochloride |
Inferred relationship |
Some |
1 |